This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
Conditions: Head and Neck Cancer; Melanoma; HPV-Related Malignancy; HPV-Related Carcinoma; HPV-Related Cervical Carcinoma; HPV Positive Oropharyngeal Squamous Cell Carcinoma; Lung Cancer, Nonsmall Cell; Melanoma (Skin)
Intervention: Diagnostic Test: Tumor Profiling
Sponsor: Repertoire Immune Medicines
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
October 1, 2021 /
/ in Oncology